


A NEW MODEL FOR COLLABORATIVE RESEARCH IN CLINICAL ONCOLOGY




PROFESSIONAL, EFFICIENT, AND FLEXIBLE STRUCTURE FOCUSED ON SCIENTIFIC VALUE

MEDSIR has more than a decade of experience developing strategic clinical trials in oncology, by combining the medical knowledge of our KOLs network, with a multidisciplinary expertise in clinical trials.

Our innovative strategies lead to the generation of groundbreaking collaborative trials that respond to unmet clinical need while complementing the internal development program of your drug.

OUR SITE NETWORK



11 years of life

48
STUDIES DEVELOPED

232
HOSPITALS working with us

100M€
acquired in the investigation againsts cancer

31
PHARMACEUTICALS & BIOTECHS have bet on our work

2.310
PATIENTS ENROLLED

86
KOLS generating innovative ideas for clinical research

434
ONCOLOGISTS in our operational network

OUR NETWORK OF ONCOLOGISTS

PIs who rely for their clinical trials strategy on us:

86

PIs participating in our clinical studies:

434

Our PIs expertise

BREAST

LUNG

GU CANCER

NUCLER MEDICINE

GY CANCER

SOLID TUMORS

GASTRO-INTESTINAL

BRAIN TUMOR AND BRAIN METS


OUR STRENGTHS:

- Experience in running global trials
- Solid Network of KOLs advising on your strategy
- Multidisciplinary expertise covering 360° of collaborative clinical trials
- Internal Translational Expertise through connections with TOP researchers and companies

OUR KNOW-HOW

- Window of opportunities
- Phase 1 B: bayesian and 3+3 designs
- Phase 2: early and advance settings, proof of concept, Simon's Two-Stages, adaptative trials, small trials (30-100 patients), big trial (200-800 patients).
- Phase 3: pivotal studies

LIFECYCLE OF A MEDSIR PROJECT



QUICK FROM STARTING GATE TO FINISH LINE

Some of our KOLs and Collaborators

ADITYA BARDIA
Harvard Medical School, United States

ANTONIO CALLES
Gregorio Marañon University General Hospital, Spain

ARSELA PRELAJ
Istituto Nazionale dei Tumori Foundation - IRCCS, Italy

BRANKO CUGLIEVAN
MD Anderson Cancer Center, United States

CARLOS BARRIOS
Grupo Oncoclinicas, Hospital Sao Lucas da PUCRS, Brazil

GIUSEPPE BANNA
Portsmouth Hospitals University NHS Trust, United Kingdom

JAUME CAPDEVILA
Vall d'Hebron University Hospital, Spain

JOAN CARLES
Vall d'Hebron University Hospital, Spain

MASSIMO CRISTOFANILLI
Weill Cornell Medicine, United States

MATTHIAS PREUSSER
Medical University of Vienna, Austria

NATALIYA UBOHA
University of Wisconsin Carbone Cancer Center, United States

PABLO MAROTO
Hospital de Sant Pau i la Creu, Spain

RAFAEL ROSELL COSTA
Istituto Oncologico Dr. Rosell, Spain

RUPERT BARTSCH
Medical University of Vienna, Austria

SANTIAGO VITERI
UOMi Cancer Center, Spain

SARA HURVITZ
University of California San Francisco Comprehensive Cancer Center, United States

ANTONIO LLOMBART CUSSAC
Arnau de Vilanova Hospital, Valencia, Spain

JAVIER CORTÉS
International Breast Cancer Center-IBCC, Spain

GIUSEPPE CURIGLIANO
Istituto Europeo di Oncologia-IEO, Italy

ALFREDO ADDEO
Hôpital Universitaires de Genève, Switzerland

NAOTO UENO
University of Hawai'i Cancer Center, United States

A JOURNEY THROUGH OUR PROJECTS Where Innovation Meets Results

MIRADOR

PoC Phase II, ctDNA driven study
PIs: Antonio Llombart, Javier Cortés

HR+/HER2-EBCz
7 Countries
67 Satellite Sites
Enrollment 1260 pts
40 on treatment

PHERGAIN

Phase II of chemotherapy de-escalation via PET-metabolic response
PIs: Antonio Llombart, José Perez

HER2+ EBC
7 Countries
56 Sites
377 pts
ASCO 2023 Plenary

LUPER

Phase Ib of dose ranging of PM01183 with a fixed dose of pembrolizumab, followed by phase II
PI: Antonio Calles

Relapsed SCLC
28 pts
1 Country
3 Sites
ESMO 2023 Mini Oral

EXCAAPE

Phase II study of Rad-223 Activity in Asymptomatic Patients With mCRPC
PI: Joan Carles Galcerán

mCRPC
1 Country
3 Satellite Sites
52 pts

I3LUNG

AI-based Retrospective & Prospective Observational Study
PI: Arselja Prelaj

mNSCLC
2000 Retrospective
200 prospective
10 Countries
6 Partners
Funded by the European Union

TUXEDO-3

Phase II basket trial for HER3-DXd in solid tumors with brain metastasis & LMD
PI: Matthias Preusser, Rupert Bartsch

Solid Tumors
Active Brain Mets
LMD
60 pts
2 Countries
9 Sites

SOME OF OUR SCIENTIFIC AND CLINICAL COLLABORATORS:



SOME OF OUR INDUSTRY COLLABORATORS:



info@medsir.org
www.medsir.org

Barcelona, Spain | New Jersey, USA